Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bionovo moves treatment for menopausal symptoms into phase II
The clinical trial will take place at four academic centers – University of California, the University of Minnesota, the University of Tennessee, and the University of Alabama. “Recent
The clinical trial will take place at four academic centers – University of California, the University of Minnesota, the University of Tennessee, and the University of Alabama. “Recent
All patients who complete the phase III clinical trial will be offered the opportunity to receive Alzhemed in the extension study, to be initiated in the second quarter
The patent issue follows an announcement of a notice of allowance in mid-January. The patent provides further coverage of cancer treatment using organic arsenic, including ZIO-101, in combination
The three trials each enrolled approximately 40 patients who have either undergone cholecystectomy, hernia repair or total knee replacement surgery. In all three trials, patients were randomized to
The initial project, bio-simulation of BioLineRx’s patented BL-1020 for the treatment of schizophrenia, will serve as a proof of concept using Optimata’s technology and provide a basis for
The compound, IT-101, is a combination of Insert’s patented polymer technology, Cyclosert, and the anticancer compound camptothecin. The application seeks to assess the formula in patients with unresectable
ISIS 301012, a second-generation antisense drug, inhibits apoB-100, a protein critical to the synthesis and transport of the “bad” cholesterol, low density lipoprotein cholesterol (LDL-C) and very low
The new worldwide licensing agreement expands a previous one, under which Oscient had rights to the drug in the US and Canada only. Oscient will now assume full
Transgenomic has granted NorDiag exclusive European commercial rights to use its proprietary Wave System and associated consumables to perform molecular diagnostic testing for the detection of colorectal and
Under the terms of the extended agreement, the companies will continue their research collaboration for a minimum of three years, with options to extend the alliance for an